John Mulligan | BiotechTV

top of page

11 hours ago

Bonum Therapeutics aims to lower the toxicity of medicines such as cytokines by regulating them via a unique sensor domain that is designed to activate a therapeutic at its target

Founder & CEO John Mulligan describes how he and his team sold an asset using the same science to Roche in 2022 for $250 million when...

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

At Savills, the Life Sciences Team specializes in helping biotech companies unlock their full potential by aligning real estate strategies with their scientific and business goals. As a leading global commercial real estate advisory firm, we focus exclusively on occupier services and tenant representation, acting as a trusted partner to some of the most innovative companies in the industry.

Visit Savills' Life Sciences Overview

bottom of page

Bonum Therapeutics aims to lower the toxicity of medicines such as cytokines by regulating them via a unique sensor domain that is designed to activate a therapeutic at its target

Follow BiotechTV

Sponsors

Sponsor Spotlight